UBS Group’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $45.6M | Buy |
727,110
+380,290
| +110% | +$30.4M | 0.01% | 1735 |
|
|
2025
Q4 | $33.1M | Buy |
346,820
+67,300
| +24% | +$6.6M | 0.01% | 2068 |
|
|
2025
Q3 | $27.3M | Buy |
279,520
+62,600
| +29% | +$6.48M | ﹤0.01% | 2228 |
|
|
2025
Q2 | $23.3M | Sell |
216,920
-55,202
| -20% | -$5.59M | ﹤0.01% | 2218 |
|
|
2025
Q1 | $27.5M | Sell |
272,122
-137,890
| -34% | -$13.9M | 0.01% | 2043 |
|
|
2024
Q4 | $36.6M | Buy |
410,012
+89,800
| +28% | +$7.91M | 0.01% | 1741 |
|
|
2024
Q3 | $26.8M | Buy |
320,212
+34,700
| +12% | +$2.74M | 0.01% | 1598 |
|
|
2024
Q2 | $22M | Buy |
285,512
+40,912
| +17% | +$2.99M | 0.01% | 1602 |
|
|
2024
Q1 | $16.8M | Sell |
244,600
-40,000
| -14% | -$2.57M | ﹤0.01% | 1834 |
|
|
2023
Q4 | $16.5M | Hold |
284,600
| – | – | ﹤0.01% | 1725 |
|
|
2023
Q3 | $15M | Buy |
284,600
+93,700
| +49% | +$4.91M | 0.01% | 1685 |
|
|
2023
Q2 | $10.3M | Buy |
190,900
+150,900
| +377% | +$7.88M | ﹤0.01% | 1941 |
|
|
2023
Q1 | $2M | Sell |
40,000
-220,100
| -85% | -$10.4M | ﹤0.01% | 3431 |
|
|
2022
Q4 | $12M | Buy |
260,100
+80,000
| +44% | +$3.46M | ﹤0.01% | 1782 |
|
|
2022
Q3 | $6.97M | Buy |
180,100
+53,500
| +42% | +$2.15M | ﹤0.01% | 2073 |
|
|
2022
Q2 | $4.72M | Sell |
126,600
-69,900
| -36% | -$2.85M | ﹤0.01% | 2428 |
|
|
2022
Q1 | $8.7M | Buy |
196,500
+115,100
| +141% | +$4.99M | ﹤0.01% | 2049 |
|
|
2021
Q4 | $3.46M | Sell |
81,400
-151,166
| -65% | -$6.35M | ﹤0.01% | 3228 |
|
|
2021
Q3 | $10.1M | Sell |
232,566
-46,042
| -17% | -$2.04M | ﹤0.01% | 2021 |
|
|
2021
Q2 | $11.9M | Buy |
278,608
+4,830
| +2% | +$203K | ﹤0.01% | 1888 |
|
|
2021
Q1 | $10.6M | Buy |
273,778
+260,308
| +1,933% | +$9.85M | ﹤0.01% | 1908 |
|
|
2020
Q4 | $484K | Sell |
13,470
-12,480
| -48% | -$450K | ﹤0.01% | 4621 |
|
|
2020
Q3 | $992K | Sell |
25,950
-12,670
| -33% | -$488K | ﹤0.01% | 3650 |
|
|
2020
Q2 | $1.36M | Buy |
+38,620
| New | +$1.39M | ﹤0.01% | 3241 |
|
|
2020
Q1 | – | Sell |
-43,900
| Closed | -$1.99M | – | 7971 |
|
|
2019
Q4 | $1.99M | Buy |
+43,900
| New | +$1.84M | ﹤0.01% | 3550 |
|
|
2019
Q1 | – | Sell |
-845,000
| Closed | -$29.9M | – | 7742 |
|
|
2018
Q4 | $29.9M | Buy |
845,000
+599,500
| +244% | +$21.7M | 0.01% | 838 |
|
|
2018
Q3 | $9.45M | Buy |
245,500
+184,700
| +304% | +$6.45M | ﹤0.01% | 1828 |
|
|
2018
Q2 | $1.99M | Buy |
+60,800
| New | +$1.83M | ﹤0.01% | 3176 |
|
|
2018
Q1 | – | Sell |
-45,900
| Closed | -$1.14M | – | 7814 |
|
|
2017
Q4 | $1.14M | Buy |
+45,900
| New | +$1.27M | ﹤0.01% | 3680 |
|
|
2017
Q2 | – | Sell |
-46,000
| Closed | -$1.14M | – | 7680 |
|
|
2017
Q1 | $1.14M | Sell |
46,000
-37,400
| -45% | -$909K | ﹤0.01% | 3424 |
|
|
2016
Q4 | $1.8M | Buy |
+83,400
| New | +$1.82M | ﹤0.01% | 3005 |
|
|
2016
Q1 | – | Sell |
-144,100
| Closed | -$2.66M | – | 7654 |
|
|
2015
Q4 | $2.66M | Buy |
144,100
+144,000
| +144,000% | +$2.58M | ﹤0.01% | 2538 |
|
|
2015
Q3 | $2K | Sell |
100
-323,200
| -100% | -$5.52M | ﹤0.01% | 8062 |
|
|
2015
Q2 | $5.72M | Sell |
323,300
-10,500
| -3% | -$188K | ﹤0.01% | 1936 |
|
|
2015
Q1 | $5.92M | Buy |
333,800
+210,100
| +170% | +$3.32M | ﹤0.01% | 1923 |
|
|
2014
Q4 | $1.64M | Buy |
+123,700
| New | +$1.58M | ﹤0.01% | 3093 |
|
Other funds holding BSX
VCM
VPM
UBS Group's BSX Position: Q1 2026 in Review
UBS Group reduced its Boston Scientific (BSX) stake by 0.32% in Q1 2026, selling an estimated $3.8M and leaving 14,824,662 shares worth $930M. The position accounts for 0.14% of the portfolio, ranked #145.
UBS Group first reported a position in BSX in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.42B in Q4 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- UBS Group held 14,824,662 shares of Boston Scientific worth $930M as of Q1 2026.
- UBS Group sold 47,464 Boston Scientific shares in Q1 2026, an estimated $3.8M.
- Boston Scientific made up 0.14% of UBS Group's portfolio in Q1 2026, its #145 holding.
- UBS Group first reported a position in Boston Scientific in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Boston Scientific position peaked at $1.42B in Q4 2025.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.